Hyaluronan (HA) has been shown to play important roles in the growth, invasion and metastasis of malignant tumors. Our previous study showing that high HA expression in malignant peripheral nerve sheath tumors (MPNST) is predictive of poor patient prognosis, prompted us to speculate that inhibition of HA synthesis in MPNST might suppress the tumorigenicity. The aim of our study was to investigate the antitumor effects of 4-methylumbelliferone (MU), an HA synthesis inhibitor, on human MPNST cells and tissues. The effects of MU on HA accumulation and tumorigenicity in MPNST cells were analyzed in the presence or absence of MU in an in vitro as well as in vivo xenograft model using human MPNST cell lines, sNF96.2 (primary recurrent) and sNF02.2 (metastatic). MU significantly inhibited cell proliferation, migration and invasion in both MPNST cell lines. HA binding protein (HABP) staining, particle exclusion assay and quantification of HA revealed that MU significantly decreased HA accumulation in the cytoplasms and pericellular matrices in both MPNST cell lines. The expression levels of HA synthase2 (HAS2) and HA synthase3 (HAS3) mRNA were downregulated after treatment with MU. MU induced apoptosis of sNF96.2 cells, but not sNF02.2 cells. MU administration significantly inhibited the tumor growth of sNF96.2 cells in the mouse xenograft model. To the best of our knowledge, our study demonstrates for the first time the antitumor effects of MU on human MPNST mediated by inhibition of HA synthesis. Our results suggest that MU may be a promising agent with novel antitumor mechanisms for MPNST.
described that extracellular HA stimulates growth, migration and invasion of various malignant tumors, 6, 7 and that increased HA levels in tumor tissues are correlated with a poor patient prognosis with malignancies such as ovarian, lung, thyroid, breast, colorectal and gastric cancers. [8] [9] [10] [11] [12] [13] Furthermore, antisense inhibition of HAS genes in tumor cells inhibits proliferation, invasion and motility in vitro and tumor growth and metastasis in in vivo models.
acid. 18 To date, several studies have investigated the antitumor effects of MU in cancer cell lines and in in vivo models. [19] [20] [21] [22] Recently, it was described that MU exerts potent antitumor effects against bone metastases of breast and lung cancers. 23, 24 However, no studies have ever analyzed the inhibitory effects of MU on soft tissue sarcoma, particularly on malignant sheath tumors. The consensus from these studies was that MU inhibits the tumorigenicity of multiple tumor cell types through inhibition of HA synthesis both in vitro and in vivo. It was also shown that MU possibly downregulates expression levels of HAS2 and/or HAS3 mRNA in several cancer cell lines. 20, 21, 23 Based on these findings, MU is thought to inhibit HA production of tumor cells in at least two ways, namely inhibition of glucuronidation and HASs expression. 20, 25 We previously demonstrated that increased HA expression in tumor tissues could be a useful marker in differentiating MPNST from neurofibroma, and in identifying patients with MPNST having a poor prognosis. 26 Based on these findings, we hypothesized that HA-targeting therapy for patients with MPNST might have potential as a novel therapeutic tool. In our study, we examined the antitumor effects of MU on human MPNST cell lines in vitro and in an in vivo mouse xenograft model.
Material and Methods

Cell culture
The human MPNST cell lines, sNF96.2 and sNF02.2, were obtained from the American Type Culture Collection (Manassas, VA). sNF96.2 cells were derived from recurrent localized tumor and sNF02.2 from lung metastatic tumor of MPNST in NF1 patients, respectively. These two MPNST cell lines, which have different background (locally recurrent and metastatic tumors), were selected because antitumor effects of MU should be evaluated with MPNST cells of various oncological behaviors. Doubling time (26 hr) of sNF02.2 was shorter than that (33 hr) of sNF96.2. The cells were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 100 U/ml penicillin and 100 lg/ml streptomycin. The cells were maintained at 378C in a humidified atmosphere with 5% CO 2 . MU was purchased from Wako Pure Chemicals (Osaka, Japan). MU for in vitro experiments was dissolved in dimethylsulfoxide (DMSO; Sigma-Aldrich, St. Louis, MO) as a stock solution, and the final concentration of DMSO in the medium was adjusted to 0.1%. To exclude the cytotoxicity of DMSO in each experiment, the cells in the control group were incubated with the same concentration of DMSO without MU. For analyses of in vitro experiments, both cell lines (sNF02.2 and sNF96.2) were used, whereas only sNF96.2 cells used for in vivo studies as hereinafter described.
HA staining for cells and tissues
HA accumulation in sNF96.2 and sNF02.2 cells and implanted tumors of sNF96.2 cells in the in vivo model was evaluated using biotinylated hyaluronic acid binding protein (b-HABP; Seikagaku, Tokyo, Japan) as previously described. 27, 28 In vitro, sNF96.2 and sNF02.2 cells were seeded in chamber slides and allowed to adhere to the bottom of the slides overnight. The cells were incubated with (1.0 mM) or without MU (0.1% DMSO) for 24 hr. The cultured cells were fixed with 4% paraformaldehyde buffered with phosphate buffered saline (PBS) at room temperature for 20 min. The slides were treated with 3% H 2 O 2 in methanol for 10 min at room temperature to block the endogenous peroxidase activity, followed by incubation with 1% bovine serum albumin (BSA) in PBS for 1 hr at room temperature. The slides were then incubated with 2.0 lg/ml b-HABP probe for 2 hr at room temperature. Bound b-HABP was detected by the addition of streptavidin-peroxidase reagents and diaminobenzidinecontaining substrate solution (Nichirei, Tokyo, Japan). The slides were counterstained with hematoxylin. The slides incubated without b-HABP were used as negative controls. For tissue staining, in vivo specimens of sNF96.2 tumors were fixed overnight with 4% paraformaldehyde buffered with PBS, and then embedded in paraffin. Sections of 5-lm thickness were deparaffinized in xylene, rehydrated through graded ethanol and subjected to HA staining as described above. Stained sections incubated without b-HABP or pretreated with 5 U/ml Streptomyces hyaluronidase for 1 hr at 608C were used as negative controls or to confirm the specificity of HABP staining.
Particle exclusion assay
Pericellular matrices were visualized using a particle exclusion assay. 29 After the treatment of sNF96.2 and sNF02.2 cells for 48 hr with (1.0 mM) or without MU (0.1% DMSO), the medium was replaced with a suspension of sheep erythrocytes
What's new?
A novel therapeutic tool is needed to improve prognosis in patients with malignant peripheral nerve sheath tumors (MPNSTs), rare and highly aggressive tumors that frequently spread despite surgical resection. Poor prognosis in MPNST is predicted by elevated expression of hyaluronan (HA). Here, HA levels were successfully suppressed by the inhibitor 4-methylumbelliferone (MU), which induced apoptosis in primary recurrent human MPSNT cells and inhibited tumor growth in a xenograft mouse model. Approved clinically as a choleretic and biliary antispasmodic agent and well-tolerated, MU is an appealing drug with novel antitumor mechanisms for MPNST.
(Sigma-Aldrich) in PBS. Visualized pericellular matrices were photographed with an inverted phase-contrast microscope. Ten cells were randomly selected at ten different fields in each treatment, and the functional pericellular matrix areas of cells were captured as digital images and measured with image analysis software (Image J; National Institutes of Health, Bethesda, MD). Labeling with Calcein AM (Sigma-Aldrich) was used to delineate the plasma membrane of sNF96.2 and sNF02.2 cells from the indistinct pericellular matrix after treatment with 1.0 mM MU. The cells were photographed using a Keyence inverted phase-contrast fluorescence microscope. The proportion of pericellular matrix areas to cell areas was evaluated as described previously. 15 A matrix area was defined by the area delineated by the pericellular matrix minus the area delineated by the plasma membrane (defined as cell area). In the absence of detectable matrices, the matrix/cell ratio would be 0.0.
Quantification of HA
Both sNF96.2 and sNF02.2 cells were incubated with (1.0 mM MU) or without MU (0.1% DMSO) for 12 hr and 24 hr. HA was isolated according to previously described methods. 30 Briefly, the conditioned medium was collected and designated as "medium." To extract the cell-surface associated HA, the cells were incubated for 10 min at 378C with trypsin-EDTA and washed with PBS. The trypsin solution and combined washes were designated as "pericellular." After cell counting, the cells were placed in Proteinase K solution (0.15 M Tris-HCl, pH 7.5, 0.15 M NaCl, 0.01 M CaCl 2 and 5 mM deferoxamine mesylate containing 20 U of proteinase K) and incubated for 2 hr at 558C, and this solution was designated as "intracellular." All samples were heated at 1008C for 15 min to inactivate protease activity and centrifuged at 15,000g for 30 min at 48C, after which the supernatants were analyzed. The HA concentrations were measured using the HA binding assay, as described previously. 31 Briefly, each well in a Maxisorp microtiter plate (Nunc, Roskilde, Denmark) was coated with 50 ll of HABP (Seikagaku, Tokyo, Japan; 0.4 lg/ml in 0.1 M NaHCO 3 , pH9.2), overnight at 48C, and subjected to blocking with 200 ll each of 2% BSA in phosphate-buffered saline with 0.1% (v/v) Tween 20 (PBS-T) at room temperature for 2 hr. After washing with PBS-T, samples (50 ll each) or standard HA solutions were applied, and the wells were incubated at 378C for 1 hr. After washing, 50 ll of biotinylated HABP (Seikagaku, Tokyo, Japan; 0.3 lg/ ml, diluted with 1% BSA/PBS-T) was added, and the plate was incubated at 378C for 1 hr. Subsequently, peroxidaseconjugated streptavidin (Jackson Immuno Research Laboratories; diluted 1:2,000 with 1% BSA/PBS-T) was applied (50 ll each) for 1 hr at 378C. After incubation with 50 ll of 3,30,5,50-tetramethylbenzidine substrate (KPL, Gaithersburg, MD) at 378C for 10 min, the absorbance at 450 nm was measured on a VERSA max microplate reader (Molecular Devices, Sunnyvale, CA). 
Cell proliferation assay
Cell migration and invasion assays
Chemotactic motility of sNF96.2 and sNF02.2 cells was investigated using 12-well cell culture chambers containing inserts with 12-lm pores (Millipore, Billerica, MA) after 24 hr of treatment with (0.1 mM and 1.0 mM) or without MU (0.1% DMSO). Invasiveness of MPNST cells was evaluated in the same chambers which contain the inserts with a 12-lm pore membrane coated with 100 lg/ml matrigel. The cells were added to the upper chamber at a density of 5 3 10 5 cells per insert in the presence or absence of MU (0.1 mM and 1.0 mM) with or without 200 lg/ml of HMWHA, and chemotactic medium containing 10% FBS was placed in the lower chamber. After incubation for 24 hr, the cells on the upper side of each membrane were removed by wiping with cotton swabs. The cells on the lower surface of the membrane were fixed with 70% ethanol and stained with hematoxylin. The cell numbers of ten different fields on the lower side were counted under a light microscope (magnification 2003).
In addition, to determine whether the effects of MU are mediated by the function of CD44, a key HA receptor, the migratory activity and invasiveness of sNF96.2 and sNF02.2 cells treated with MU were evaluated after knockdown of CD44 using siRNAs. Briefly, siRNA for hyaluronic acid receptor cell adhesion molecule (HCAM; Santa Cruz Biotechnology, Santa Cruz, CA) were complexed with Lipofectamine RNAiMAX (Invitrogen, Carlsbad, CA) in Opti-MEM (Gibco, Life Technologies) according to the manufacturer's instruction, and then the mixtures were administered to sNF96.2 and sNF02.2 cells in DMEM with serum and antibiotics. As a control siRNA, the Silencer negative control (Ambion, Austin, TX) was used. For 48 hr incubation, efficiency of knockdown with siRNA for CD44 was confirmed using real-time RT-PCR. The effects of MU on cell migration and invasion were analyzed under the condition of CD44 knockdown.
Evaluation for cell apoptosis
We examined whether the growth inhibition by MU was attributable to the induction of apoptosis. The effects of MU on cell apoptosis were measured by flow cytometry with antiAnnexin V antibody after incubation for 48 
Real-time RT-PCR
Both sNF96.2 and sNF02.2 cells were treated with (0.1 mM and 1.0 mM) or without MU (0.1% DMSO) for 6, 12 and 24 hr. Total RNA was extracted with RNeasy Micro kit (Qiagen, San Diego, CA). Reverse-transcribed cDNA was subjected to real-time RT-PCR for semi-quantification of HAS1, HAS2, HAS3 and CD44 mRNAs using a Light-Cycler (Roche Diagnostics, Mannheim, Germany). The relative expression levels of HASs and CD44 mRNAs of sNF96.2 and sNF02.2 cells were normalized with GAPDH mRNA levels. Specific oligonucleotide primer pairs were HAS1 (forward, 5
0 ) and human GAPDH (forward, 5 0 -TGCA CCACCAACTGCTTAGC-3 0 ; reverse, 5 0 -GGCATGGACTG TGGTCATGAG-3 0 ). The mRNA level at each time point was shown as a ratio to the control cultures with the medium containing 0.1% DMSO.
MPNST xenograft model
Animal experiments were approved by the Animal Research Committee of our institution. Six-week-old female athymic nude mice (BALB/C nu/nu mice; SLC, Shizuoka, Japan) were used in our study. To establish the xenograft model, two human MPNST cell lines, sNF96.2 and sNF02.2, were injected subcutaneously into the flanks of the mice at a concentration of 2 3 10 7 cells in 200 ll suspension of PBS. Tumors routinely developed in mice injected with sNF96.2 cells, but not with sNF02.2 cells. For in vivo passage, the developed sNF96.2 tumors were harvested from the mice, minced in PBS by homogenization at lowest speed, and 100 ll of homogenized solution was reimplanted into the flank of other tumor-naive mice according to the protocol described by Faltz et al. 32 When implanted tumor volumes reached approximately 100 mm 3 , mice were randomized into two groups (n 5 8 each). In the MU-treated group, MU (10 mg/ body weight; approximately equal to 400-500 mg/kg) dissolved in 100 ll of 0.4% carboxymethylcellulose (CMC) solution (Sigma-Aldrich) was administered intraperitoneally daily for 6 weeks. We previously reported that systemic administration of MU (10 mg/body weight; 400-500 mg/kg) did not affect the structure of normal skin, articular cartilage and body weight in mouse bone metastasis model. 23 In the control group, the same amount of 0.4% CMC solution without MU was administered intraperitoneally to the mice for 6 weeks. Tumors were monitored twice a week. Tumor size was determined with a caliper, and the volume was calculated by the formula V (mm 
Immunohistochemical staining for Ki67
Ki67 protein is widely known as an appropriate and useful marker of the proliferating fraction within a given cell population. We performed Ki67 immunostaining for xenograft tumors to examine the effects of MU on the proliferation in vivo. Deparaffinized and rehydrated sections were treated with 0.3% H 2 O 2 in methanol for 30 min to block the internal peroxidase activity. The sections were incubated with mouse anti-human Ki67 monoclonal antibody (Dako, Glostrup, Denmark) as a primary antibody (dilution; 1:500) using Histofine MOUSESTAIN KIT (Nichirei, Tokyo, Japan) according to the manufacturer's instructions. Biotinylated anti-mouse goat IgG (Nichirei, Tokyo, Japan) was applied as a secondary antibody for 30 min at room temperature, and antibody binding was detected by the addition of streptavidinperoxidase reagents and diaminobenzidine-containing substrate solution (Nichirei, Tokyo, Japan). Five fields (magnification 4003) were randomly selected in each section. Ki67-positive cells of these fields were counted and divided by the total number of tumor cells in each field. Three tumors each from the control and MU-treated mice were analyzed.
Statistical analysis
All the quantitative experiments in vitro were performed more than three times. Bonferroni-Dunn post hoc test was used to assess the differences between means in multiple groups, and Mann-Whitney U test or Student's t-test was used to distinguish differences between two groups. p values of <0.05 were considered statistically significant.
Results
HA staining in cells
Both sNF96.2 and sNF02.2 cells treated with the control medium (0.1% DMSO) without MU for 24 hr showed prominent staining for HA in cytoplasms of tumor cells (Fig. 1a) . The positivity for HA was decreased, but not completely abrogated after 24 hr treatment with 1.0 mM MU in both MPNST cell lines. The MU treatment caused morphological change of cells, particularly reduced formation of cell processes and filopodia-like structures in sNF02.2, as compared to the cells treated with control cultures (0.1% DMSO) (arrowheads, Fig. 1a ).
Particle exclusion assay
As shown in Figure 1b 
Cell proliferation
Preliminary experiments revealed that cell viability of each cell line incubated with 1.0 mM MU for 24 and 48 hr was >95% by Trypan Blue Exclusion assay. Treatment with 0.1 mM and 1.0 mM MU significantly inhibited the proliferation of sNF96.2 and sNF02.2 cells in a dose-and timedependent manner, compared to the cells treated without MU (Fig. 3a and 3b , respectively). Even with a concentration of 0.1 mM MU treatment, cell proliferation was significantly reduced. Maximal reduction was obtained at a concentration of 1.0 mM in both sNF96.2 and sNF02.2 cells. Exogenously added HMWHA did not recover the inhibition of cell proliferation by MU in both MPNST cells.
Cell migration and invasion assays
At the 24 hr time point of cell culture, the migratory activity of sNF96.2 and sNF02.2 cells treated with 1.0 mM MU was significantly suppressed compared to the cells with control 
Real-time RT-PCR
To determine the effects of MU on HA synthesis at messenger levels in human MPNST cells, HAS1-3 and CD44 mRNA expression were analyzed. HAS1 mRNA was undetectable by RT-PCR in both sNF96.2 and sNF02.2 cell lines (data not shown), and so we determined the HAS2, HAS3 and CD44 mRNA levels in sNF96.2 and sNF02.2 cells. Treatment with 1.0 mM MU for 12 hr significantly reduced mRNA 
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expression of HAS2 in both sNF96.2 and sNF02.2 cell lines compared to that in the control cultures (p < 0.001 and p 5 0.009, respectively; Fig. 3f ). Expression levels of HAS3 mRNA in sNF96.2 cells treated with 0.1 mM and 1.0 mM MU were significantly downregulated compared to those in the control cultures (p < 0.001 and p < 0.001; respectively, Fig. 3g ). In sNF02.2 cells, HAS3 mRNA was also decreased by MU in a dose-dependent manner, with the reduction, however, not reaching statistical significance (Fig. 3g) . Timecourse analyses revealed that 1.0 mM MU significantly reduced mRNA expression of HAS2 in both MPNST cell lines at every time point, except at 24 hr of sNF96.2 cells. Expression levels of HAS3 mRNA were downregulated in a time-dependent manner by 0.1 mM and/or 1.0 mM MU in sNF96.2 cells and sNF02.2 cells (Supporting Information Fig.  S2 ). Expression level of CD44 mRNA in sNF96.2 cells and sNF02.2 cells treated with 0.1 mM or 1.0 mM MU varied according to periods of incubation and types of cell lines (Supporting Information Fig. S2 ).
Knockdown of CD44
To investigate whether a main hyaluronan receptor, CD44, affect the results of MU treatment, effects of siRNA knockdown for CD44 on tumorigenicity in sNF96.2 and sNF02.2 cells were evaluated. After knockdown, CD44 mRNA expression was decreased to <10% of control siRNA in both cell lines. Interestingly, CD44 knockdown itself had inhibitory effects of cell migration and invasiveness in both cell lines. Cotreatment of siRNA CD44 and MU had additive inhibitory effects of migration and invasion in sNF96.2 and sNF02.2 cells (Supporting Information Fig. S3 ). However, these results could not conclude that MU effects are mediated by CD44 or not.
Tumor growth in the xenograft model
Two human MPNST cell lines, sNF96.2 and sNF02.2, were injected in the flank of nude mice. In vivo tumorigenicity was confirmed only in sNF96.2 cell injected mice. Daily administration of MU (10 mg/body weight) for 6 weeks significantly suppressed the increase of tumor volume of sNF96.2 compared to that with control treatment (4W; p 5 0.007, 5W; p 5 0.074 and 6W; p 5 0.006, respectively; Fig. 4a ) and tumor weight (p 5 0.047; Fig. 4b) , as compared to those of the control mice treated with a vehicle (Fig. 4c) . Positivity for HA of tumor cells and stromal tissues was suppressed with MU treatment [ Fig. 4d(i-iv) ]. Immunostaining of Ki67, which is a marker for cell proliferation, revealed that the ratio of Ki67-positive cells in tumor cells of MU-treated mice was significantly reduced compared to that of vehicle-treated mice[ Fig.  4d (v-vi)] (p 5 0.002, Fig. 4e ). The body weight of mice was measured twice a week during the drug administration. There was no statistical difference in body weight between the mice treated and untreated with MU at each time point (Fig. 4f) . Body weight excluding tumor weight also did not differ between the control and MU-treated mice after the treatment for 6 weeks (p 5 0.147).
Discussion
In general, the clinical outcome of patients with advanced MPNST is dismal. Doxorubicin and ifosfamide are currently the most active chemotherapeutic agents in patients with unresectable and metastatic soft tissue sarcomas; however, the response evaluation criteria in solid tumors response rate for the combination is reported to be only approximately 26%. 33 The responses were no better in patients with MPNST, shown to be 21% in a multiinstitution retrospective study for patients with unresectable and metastatic MPNST. 34 A novel therapeutic tool other than existing chemotherapeutic agents is thus urgently required to improve the prognosis of patients with advanced MPNST.
Recently, Slomiany et al. reported that HA oligomers suppressed HA secretion in MPNST cells, decreased doxorubicin resistance of MPNST and suppressed the growth of MPNST xenografts in mice, which implicated the importance of HA in the tumorigenicity of MPNST. 35 Our previous study demonstrated that increased HA expression in MPNST tissues significantly correlated with poor prognosis in patients with MPNST. 26 Based on these results, there is a great need to identify pharmacologic agents that effectively inhibit HA synthesis for MPNST, and are also clinically applicable.
Several studies have shown the antitumor effects of MU in various malignancies mediated by inhibition of HA synthesis. [19] [20] [21] [22] [23] [24] [25] [36] [37] [38] It was reported that the inhibitory effects of MU on cell migration and invasion could be explained by inhibition of extracellular matrix formation through inhibition of HA synthesis in several cancer cell lines. 19, 23, 24, 39 However, these studies examined the antitumor effect of MU primarily focused on cancer cells of epithelial origin. The behavior of mesenchymal cells may differ from that of epithelial cells because mesenchymal cells likely have more abundant HA-rich matrices compared to epithelial cells. The antitumor effects of MU in mesenchymal malignancies appeared to differ from those in epithelial malignancies. The results of the particle exclusion assay in our study revealed that MPNST cells had abundant pericellular matrices, which were larger than the pericellular matrix formation previously reported in cancer cells such as melanoma and pancreatic cancer cells. 19, 22 Previous studies described that the inhibition of pericellular matrices via inhibition of HA accumulation resulted in reduced tumorigenicity of osteosarcoma cells. 14, 15 In our study, MU treatment significantly decreased the amount of pericellular matrices concurrently with the reduction of the concentrations of intracellular and pericellular HA determined with HA binding assay in both sNF96.2 and sNF02.2 cells. These results implied that the depletion of pericellular matrix formation might be partly attributable to the depletion of HA by MU treatment in MPNST cells. Furthermore, HA staining in vitro revealed that MU inhibited accumulation of pericellular HA in MPNST cells, and diminished the filopodia-like structure after MU treatment in our study, which was consistent with a previous report. 23 These suggest that morphological change of cells possibly induced by HA depletion with MU treatment might contribute in a significant way to the inhibition of tumorigenicity. On the other hand, exogenously added HA could not cancel the effects of MU in our study, which is inconsistent with the results in prostate cancer cells. 21 Newly synthesized HA bound to the HA synthase complex rather than non-bound HA in extracellular matrix might be important to maintain tumorigenicity of MPNST.
MU was reported to suppress mRNA levels of HAS2 and/ or HAS3 in several carcinoma cell lines in a dose-dependent manner. 20, 21, 23 Kultti et al. reported that a dose-dependent reduction by MU in the mRNA levels of HAS2 or HAS3, or both, was detected in four different cancer cell lines, and that alterations of the mRNA levels depended on the kind of tumor. 20 Results of these reports are consistent with the Cancer Therapy and Prevention 40 Li et al. described that siRNA-mediated knockdown of HAS2 suppressed cell growth and cellular migratory and invasive potential in human breast cancer cells. 17 Taken together with the results of these previous studies, MU was thought to inhibit the tumorigenicity of MPNST cells partly through repression of HAS2 and/or HAS3 mRNA in our study. However, it has not yet been elucidated how MU downregulated the levels of HASs mRNA at the molecular level.
In our study, the proliferation of sNF96.2 and sNF02.2 cells was significantly suppressed by MU, supporting previous data on other types of tumor cell. 15, [20] [21] [22] [23] [24] 36 The apoptotic activity of sNF96.2 cells was induced by MU treatment, whereas that of sNF02.2 was not. Recent studies demonstrated that MU treatment was associated with growth arrest and apoptosis of tumor cells, 21, 23, 37 whereas Edward et al. reported that MU had no effect on apoptosis of melanoma cells, 38 suggesting that stimulation of apoptosis may be tumor-type dependent, and/or vary among cell lines of the same malignant neoplasms.
Our study also examined the antitumor effects of MU in a xenograft model of MPNST. Tumors developed in the sNF96.2 cell transplanted mice, but not in sNF02.2 cell transplanted ones. Considering that sNF96.2 cells were derived from locally recurrent MPNST and sNF02.2 cells from metastatic MPNST of lung, a possible explanation was that the affinity of these cells for host tissues of mice ("seed and soil" theory) might affect the establishment of xenograft tumors. Another explanation might be that MPNST is a group of extremely heterogeneous tumors, particularly with regard to their genomic alterations, which will affect the development of tumors in vivo. Our previous report investigating HASs expression in human MPNST tissues showed that expression patterns of HAS1, 2 and 3 were markedly heterogeneous among cases. 26 MU significantly reduced the growth rate of sNF96.2 tumors in the xenograft model, possibly mediated by reduced deposition of HA in tumorous and stromal tissues. MU could not show the effects of tumor shrinkage, but have "tumor-dormancy" effects for MPNST.
The molecular mechanisms underlying MPNST development and progression are not fully understood. Although several preclinical studies are underway to develop a targeted therapy for MPNST based on molecular approaches, successful results of clinical trials with novel agents are absent. As NF1 gene product, neurofibromin, acts as a negative regulator in the Ras signal transduction pathway, several studies evaluating potential treatments for MPNST have focused on the compounds that block Ras signaling, such as farnesyl transferase inhibitors or mTOR inhibitors. [41] [42] [43] Other studies have investigated targeted therapies for molecules such as erlotinib (EGFR inhibitor), sorafenib (VEGFR and RAF inhibitor) and imatinib mesylate (tyrosine-kinase inhibitor). [44] [45] [46] These compounds have shown positive effects in vitro and/or in in vivo studies, while demonstrating a limitation as a single agent in human clinical trials. [47] [48] [49] [50] [51] It is suggested that a major problem of a target therapy for signal pathways may be the capability of tumor cells to mutate and use alternate pathways for survival and proliferation thereby escaping specific inhibitor action. "Second hits" other than NF1 mutation vary among MPNSTs, making it difficult to target a single pathway for therapy of MPNSTs. Therefore, additional therapeutic approaches relying on other antitumor mechanisms are more likely to be needed in patients with MPNST.
MU is already an established therapeutic agent for choleretic and biliary antispasmodic activity. 25 The clinical experience to date also reveals that MU is a safe and well-tolerated oral medication. Our results showed that MU suppressed cell growth in vitro and in vivo, increased apoptosis activity and attenuated cell migration and invasion of MPNST through the inhibition of HA synthesis and possibly alteration of the tumor microenvironment. Although further investigations are warranted to clarify the efficacy and mechanisms of MU in patients with MPNST, HA-targeting therapy with MU may have potential as a novel therapeutic tool for patients with MPNST.
